13 Since then, the techniques for developing monoclonal antibodies evolved. The use of recombinant DNA led to the development of more chimeric monoclonal antibodies and later extended this strategy to ...

Monoclonal antibodies (mAbs) are nature's biological ... reaching a “peak” of eight products during the year 1991 (see Fig. 1). Chimeric mAbs were less evident: Between two and four products ...

Animal testing requirements for monoclonal antibodies and other medications will be “reduced, refined or potentially replaced ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Using a monoclonal antibody that binds to CD20 will therefore ... Some are referred to as chimeric, such as rituximab, which means the bioengineers used a 'mix of construction materials' to ...

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related ...

a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre ...

a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre ...

The human anti-mouse antibody (HAMA) reaction limits the therapeutic utility of mouse monoclonal antibodies. Humanization of mouse monoclonal antibodies by genetic engineering can improve the in ...

Cokgor, I, Akabani, G, Wikstrand C, et al. Radiolabeled Monoclonal Antibodies for Malignant Glioma: An Improvement Over Current Therapy? MedGenMed 2(3), 2000 [formerly published in Medscape ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Expert Rev Resp Med. 2008;2(5):617-629. A double-blind placebo-controlled study using the TNF-α monoclonal antibody infliximab over 6 weeks in 38 patients with moderate-to-severe asthma showed no ...